Abstract
C-Type Lectin Domain Family 3 Member B (CLEC3B) encodes proteins associated with tumor invasion and metastasis. However, the interrelation between CLEC3B gene expression, tumor immunity, and prognosis of patients with hepatocellular carcinoma (HCC) is unclear. This study was conducted to investigate the prognostic potential of CLEC3B and its association with tumor tissue infiltration markers. CLEC3B expression was examined using the TIMER and Oncomine databases, with its prognostic potential assessed using the GEPIA and Kaplan–Meier plotter databases. The relationship between CLEC3B and tumor immune cell infiltration biomarkers was analyzed using TIMER. Here, we revealed that CLEC3B expression was decreased in HCC and was correlated with a poor survival rate in patients with HCC. Additionally, the expression of CLEC3B was negatively correlated with differential immune cell infiltration and various immune biomarkers. These results indicate a potential mechanism by which the expression of CLEC3B might adjust tumor immunity by modulating the infiltration of HCC immune cells. Our study demonstrated that CLEC3B could be a potential prognostic biomarker and might be involved in tumor immune cell infiltration in HCC.
Highlights
Hepatocellular carcinoma (HCC) remains to be the second most fatal cancer worldwide, with an estimated incidence rate exceeding 1 million cases per year (Bray et al, 2018; Llovet et al, 2018)
We investigated the relationship between CLEC3B expression and immune cell infiltration levels based on biomarker gene expression in various tumors under the gene module
In this study, using a bioinformatics analysis method with public resource databases, we revealed that CLEC3B expression was decreased in hepatocellular carcinoma (HCC) and was correlated with a poor survival rate in patients with HCC
Summary
Hepatocellular carcinoma (HCC) remains to be the second most fatal cancer worldwide, with an estimated incidence rate exceeding 1 million cases per year (Bray et al, 2018; Llovet et al, 2018). CLEC3B has been reported to function in the mineralization process in CLEC3B Potential Prognostic Biomarker osteogenesis and neuroprotection (Iba et al, 2013; Chen et al, 2015). It is associated with tumor invasion and metastasis via plasminogen activation, leading to extracellular proteolysis (Clemmensen et al, 1986; Obrist et al, 2004; Danø et al, 2005; Dai et al, 2019). The results indicated a potential mechanism by which the CLEC3B expression might adjust tumor immunity by modulating the infiltration of immune cells in HCC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
